Vaccinia virus (VV) proteins that interfere with the host response to infection are of interest because they provide insight into virus–host relationships and may affect the safety and immunogenicity of recombinant VV (rVV) vaccines. Such vaccines need assessment in animal models and with this aim a model of VV infection based on intradermal injection of BALB/c ear pinnae was developed and characterized. In this model, the outcome of infection is affected by the dose of virus inoculated but virus spread is minimal and the mice suffer no signs of systemic illness. Cellular and humoral immune responses to these infections were measured readily and were independent of virus dose over a 100-fold range. Thus the model seems suitable for the analysis of the safety and immunogenicity of VV mutants lacking specific immunomodulatory proteins or bearing foreign antigens.
AndrewM. E.,
CouparB. E.,
BoyleD. B.1989; Humoral and cell- mediated immune responses to recombinant vaccinia viruses in mice. Immunology and Cell Biology 67:331–337
AntoineG.,
ScheiflingerF.,
DornerF.,
FalknerF. G.1998; The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365–396
BlanchardT. J.,
AlcamíA.,
AndreaP.,
SmithG. L.1998; Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. Journal of General Virology 79:1159–1167
HansonC. V.,
RiggsJ. L.,
LennetteE. H.1978; Photochemical inactivation of DNA and RNA viruses by psoralen derivatives. Journal of General Virology 40:345–358
HillT. J.,
FieldH. J.,
BlythW. A.1975; Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. Journal of General Virology 28:341–353
LeeM. S.,
RoosJ. M.,
McGuiganL. C.,
SmithK. A.,
CormierN.,
CohenL. K.,
RobertsB. E.,
PayneL. G.1992; Molecular attenuation of vaccinia virus: mutant generation and animal characterization. Journal of Virology 66:2617–2630
MiyahiraY.,
MurataK.,
RodriguezD.,
RodriguezJ. R.,
EstebanM.,
RodriguesM. M.,
ZavalaF.1995; Quantification of antigen specific CD8+ T cells using an ELISPOT assay. Journal of Immunological Methods 181:45–54
MoorheadJ. W.,
ClaytonG. H.,
SmithR. L.,
SchaackJ.1999; A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears. Journal of Virology 73:1046–1053
NelsonJ. B.1938; The behaviour of poxviruses in the respiratory tract. I. The response of mice to the nasal instillation of vaccinia virus. Journal of Experimental Medicine 68:401–412
SchneiderJ.,
GilbertS. C.,
BlanchardT. J.,
HankeT.,
RobsonK. J.,
HannanC. M.,
BeckerM.,
SindenR.,
SmithG. L.,
HillA. V.1998; Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine 4:397–402
TartagliaJ.,
PerkusM. E.,
TaylorJ.,
NortonE. K.,
AudonnetJ. C.,
CoxW. I.,
DavisS. W.,
van der HoevenJ.,
MeignierB.,
RiviereM.and others1992; NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217–232